• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

耐多药结核病患者中影响Cat-IV方案反应和结局的因素研究。

Study of factors influencing response and outcome of Cat-IV regimen in MDRTB patients.

作者信息

Yadav Arun Kumar, Mehrotra Ashok Kumar, Agnihotri S P, Swami Shivani

机构信息

Associate Professor, Department of Respiratory Medicine, NIMS Medical College, Jaipur, Rajasthan, India.

Associate Professor, Department of Respiratory Medicine, NIMS Medical College, Jaipur, Rajasthan, India.

出版信息

Indian J Tuberc. 2016 Oct;63(4):255-261. doi: 10.1016/j.ijtb.2016.09.013. Epub 2016 Nov 22.

DOI:10.1016/j.ijtb.2016.09.013
PMID:27998499
Abstract

BACKGROUND

CAT IV regimen or the standardized drug regimen (SDR) under the Revised National Control Program (RNTCP) uses six second-line anti-tubercular drugs in the initial intensive phase (IP). These drugs have many side effects and toxicity; they are less efficacious and have poor acceptability. The present study was conducted to evaluate the efficacy and outcome of Cat-IV regimen and the factors which influence the treatment outcome in MDR TB patients.

METHODS

It was a prospective observational study, which was done in the CAT II treatment failure, LPA proven MDR TB patients, above the age of 18 years, who were referred to DOTS Plus center for treatment. The study was approved by the hospital ethics committee and patient consent was obtained before inclusion.

RESULTS

We observed culture conversion in 63.04% and ADR in 96.5%, default in 15.65%, and death in11.3% cases. The factors which influenced outcome included low body weight, long duration of illness cavitatory disease and indulgence in both tobacco & alcohol. The radiological favorable response strongly and significantly correlated with the bacteriological and clinical response during the IP.

CONCLUSION

We suggest that the efficacy can be further augmented by reducing default and controlling deaths which accounts for substantial numbers and occur mostly during IP.

摘要

背景

在修订后的国家结核病控制规划(RNTCP)下,第四类方案(CAT IV)或标准化药物方案(SDR)在初始强化期(IP)使用六种二线抗结核药物。这些药物有许多副作用和毒性;它们疗效较差且可接受性不佳。本研究旨在评估第四类方案的疗效和结局以及影响耐多药结核病患者治疗结局的因素。

方法

这是一项前瞻性观察性研究,针对年龄在18岁以上、经CAT II治疗失败且经线性探针分析(LPA)证实为耐多药结核病的患者,这些患者被转诊至DOTS Plus中心进行治疗。该研究经医院伦理委员会批准,并在纳入研究前获得患者同意。

结果

我们观察到63.04%的患者培养转阴,96.5%的患者出现药物不良反应,15.65%的患者中断治疗,11.3%的患者死亡。影响结局的因素包括体重低、病程长、有空洞性病变以及吸烟和饮酒。在初始强化期,影像学上的良好反应与细菌学和临床反应密切且显著相关。

结论

我们建议,通过减少中断治疗和控制死亡人数(这些情况占相当比例且大多发生在初始强化期),可以进一步提高疗效。

相似文献

1
Study of factors influencing response and outcome of Cat-IV regimen in MDRTB patients.耐多药结核病患者中影响Cat-IV方案反应和结局的因素研究。
Indian J Tuberc. 2016 Oct;63(4):255-261. doi: 10.1016/j.ijtb.2016.09.013. Epub 2016 Nov 22.
2
Revised Category II regimen as an alternative strategy for retreatment of Category I regimen failure and irregular treatment cases.修订后的 II 类方案可作为 I 类方案失败和不规则治疗病例再治疗的替代策略。
Am J Ther. 2011 Sep;18(5):343-9. doi: 10.1097/MJT.0b013e3181dd60ec.
3
Outcome of multi-drug resistant tuberculosis cases treated by individualized regimens at a tertiary level clinic.三级诊所采用个体化方案治疗耐多药结核病病例的结果。
Indian J Tuberc. 2008 Jan;55(1):15-21.
4
Isolation of Mycobacterium tuberculosis from sputum of tribal, non-tribal pulmonary tuberculosis patients of Andaman & Nicobar islands by conventional culture method and assessment of first line anti-tuberculosis drug susceptibility patterns.通过传统培养方法从安达曼和尼科巴群岛部落及非部落肺结核患者痰液中分离结核分枝杆菌,并评估一线抗结核药物敏感性模式。
Indian J Tuberc. 2015 Jan;62(1):23-8. doi: 10.1016/j.ijtb.2015.02.004. Epub 2015 Mar 7.
5
Multidrug-resistant tuberculosis of the spine--is it the beginning of the end? A study of twenty-five culture proven multidrug-resistant tuberculosis spine patients.脊柱耐多药结核病——是否意味着终结的开始?对 25 例培养证实的耐多药结核脊柱患者的研究。
Spine (Phila Pa 1976). 2009 Oct 15;34(22):E806-10. doi: 10.1097/BRS.0b013e3181af7797.
6
Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis.美国疾病预防控制中心(CDC)临时使用和安全监测苯并恶嗪盐酸盐(Sirturo)治疗耐多药结核病的指南。
MMWR Recomm Rep. 2013 Oct 25;62(RR-09):1-12.
7
Multidrug-resistant TB among previously treated TB cases: A retrospective study in Nagpur, India.既往治疗过的结核病病例中的耐多药结核病:印度那格浦尔的一项回顾性研究。
Indian J Tuberc. 2015 Oct;62(4):207-10. doi: 10.1016/j.ijtb.2015.11.002. Epub 2016 Jan 23.
8
API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.《2006年抗结核药物国际共识指南:肺结核、肺外结核及特殊情况结核病的管理》
J Assoc Physicians India. 2006 Mar;54:219-34.
9
Representative drug susceptibility patterns for guiding design of re-treatment regimens for multidrug-resistant tuberculosis in Iran.指导伊朗耐多药结核病再治疗方案设计的代表性药敏模式。
Respirology. 2008 Jan;13(1):108-11. doi: 10.1111/j.1440-1843.2007.01201.x.
10
Cost-effectiveness of treating multidrug-resistant tuberculosis.治疗耐多药结核病的成本效益
PLoS Med. 2006 Jul;3(7):e241. doi: 10.1371/journal.pmed.0030241.

引用本文的文献

1
Performance evaluation of alternative bacteriological measures of response to MDR-TB therapy during the initial 16 weeks of treatment.耐多药结核病治疗最初16周期间替代细菌学反应指标的性能评估
Res Sq. 2025 Apr 10:rs.3.rs-5834681. doi: 10.21203/rs.3.rs-5834681/v1.
2
Failure or relapse predictors for the STREAM Stage 1 short regimen for RR-TB.STREAM 阶段 1 短程方案治疗 RR-TB 的失败或复发预测因素。
Int J Tuberc Lung Dis. 2022 Aug 1;26(8):753-759. doi: 10.5588/ijtld.22.0073.
3
Treatment outcome of multidrug-resistant tuberculosis with modified DOTS-plus strategy: A 2 years' experience.
采用改良强化间歇短程化疗策略治疗耐多药结核病的疗效:两年经验
Lung India. 2019 Sep-Oct;36(5):384-392. doi: 10.4103/lungindia.lungindia_475_18.
4
Treatment Outcomes Associated with Multidrug-resistant Tuberculosis.与耐多药结核病相关的治疗结果
J Glob Infect Dis. 2018 Jul-Sep;10(3):125-128. doi: 10.4103/jgid.jgid_96_17.